NCT04185779 COLO-COHORT (Colorectal Cancer Cohort) Study
| NCT ID | NCT04185779 |
| Status | Recruiting |
| Phase | — |
| Sponsor | South Tyneside and Sunderland NHS Foundation Trust |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2019-12-13 |
| Primary Completion | 2024-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2019-12-13 with a primary completion date of 2024-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a cross-sectional study aimed at identifying factors which best predicts patients at high risk of colorectal cancer or colorectal adenomas and to develop a risk prediction model.
Eligibility Criteria
Inclusion Criteria: Group A * Aged ≥30 years\* and able to give informed consent * Patients attending colonoscopy * Through Bowel Cancer Screening Programme (FIT positive, Bowelscope conversion, surveillance) * Through standard NHS care (most commonly due to iron deficiency anaemia, altered bowel habit, weight loss, rectal bleeding, planned polypectomy\*\*, those referred on basis of family history, abnormal cross-sectional imaging, polyp surveillance or post CRC surveillance) * The age of 30 was chosen to ensure that this is a population likely to be enriched for colorectal neoplasia with neoplasia below this age uncommon \*\*In those attending for planned polypectomy, the results from the initial colonoscopy and the endoscopy where the polypectomy is undertaken will be summated for purposes of calculating the neoplasia profile (COLO-SPEED) Group B * Any patient attending for colonoscopy and able to give informed consent * ≥ 18 years old * Patient from the North of England Exclusion Criteria: Group A * Unable to give informed consent * Known polyposis syndrome * Previous total colectomy * Known colonic stricture which would limit complete colonoscopy * Attending for planned therapeutic procedure other than polypectomy, such as insertion of colonic stent * Attending for assessment of known inflammatory bowel disease (IBD) activity or for IBD surveillance * Patients currently recruited into an interventional CTIMP for CRC prevention\* COLO-SPEED (Group B) \*\* * Unable to give informed consent * Not in a centre supported by COLO-SPEED infrastructure (North of England)
Contact & Investigator
Colin Rees
PRINCIPAL INVESTIGATOR
Newcastle University
Frequently Asked Questions
Who can join the NCT04185779 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04185779 currently recruiting?
Yes, NCT04185779 is actively recruiting participants. Contact the research team at sara.koo@stft.nhs.uk for enrollment information.
Where is the NCT04185779 trial being conducted?
This trial is being conducted at South Shields, United Kingdom, Kettering, United Kingdom, Stockton-on-Tees, United Kingdom.
Who is sponsoring the NCT04185779 clinical trial?
NCT04185779 is sponsored by South Tyneside and Sunderland NHS Foundation Trust. The principal investigator is Colin Rees at Newcastle University. The trial plans to enroll 15,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.